Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

Authors:

Abstract
Significance: Neutralizing antibodies (NAbs) against HIV-1 are under clinical development. Despite demonstrated antiviral activity when used as treatment in HIV-infected people, the mechanism of action of NAbs remains controversial. Quantification of the relative contribution of Fab-mediated (neutralization of free virus) and Fc-mediated functions such as antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and complement fixation is essential to develop better therapies. Here, we treated chronically SHIV-infected rhesus macaques with a single dose of NAb VRC07-523LS with or without Fc modifications. Fc function contributes 21% to the antiviral activity of VRC07-523LS with an unmodified Fc region, when compared to NAb with Fc knockout mutations. However, NAbs with improved ADCC function in vitro did not show enhanced antiviral activity in vivo.
Funding Information
  • HHS | NIH | National Cancer Institute (HHSN261200800001E)
  • U.S. Department of Energy (89233218CNA000001)
  • HHS | National Institutes of Health (R01-AI028433)
  • HHS | National Institutes of Health (R01-OD011095)
  • HHS | National Institutes of Health (P01-AI131365)
  • Bill and Melinda Gates Foundation (OPP1147555)
  • HHS | National Institutes of Health (Intramural)

This publication has 41 references indexed in Scilit: